Cosentyx is a biologic drug used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. According to Drug Patent Watch [1], Cosentyx is a monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine involved in the inflammatory process. Cosentyx is manufactured by Novartis and was approved by the FDA in 2015.

Drugs.com [2] provides a comparison of Cosentyx with other drugs used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. The website lists the effectiveness, side effects, and cost of each drug. In terms of effectiveness, Cosentyx is rated highly for treating psoriasis and psoriatic arthritis. It is also effective for treating ankylosing spondylitis, but other drugs such as Humira and Enbrel are rated slightly higher.

A study published in the Journal of Clinical Medicine [3] compared the effectiveness of Cosentyx with another biologic drug, Stelara, in treating psoriasis. The study found that Cosentyx was more effective than Stelara in achieving clear or almost clear skin after 16 weeks of treatment. Cosentyx was also more effective in reducing the severity of psoriasis symptoms.

In conclusion, Cosentyx is an effective biologic drug for treating psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is highly effective for treating psoriasis and psoriatic arthritis, and slightly less effective than some alternatives for treating ankylosing spondylitis. A study comparing Cosentyx with Stelara found that Cosentyx was more effective in treating psoriasis. However, the choice of drug should be made in consultation with a healthcare professional, taking into account individual factors such as the severity of the condition, potential side effects, and cost.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.drugs.com/compare/cosentyx
[3] https://pubmed.ncbi.nlm.nih.gov/32581090/